

Tao Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/595652/publications.pdf>

Version: 2024-02-01

123
papers

19,707
citations

70961

41
h-index

32761

100
g-index

127
all docs

127
docs citations

127
times ranked

39872
citing authors

#	ARTICLE	IF	CITATIONS
1	Model-based Analysis of ChIP-Seq (MACS). <i>Genome Biology</i> , 2008, 9, R137.	13.9	13,517
2	The Critical Role of RNA m6A Methylation in Cancer. <i>Cancer Research</i> , 2019, 79, 1285-1292.	0.4	505
3	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3410-3415.	3.3	425
4	The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer. <i>Cancer Research</i> , 2009, 69, 1702-1705.	0.4	360
5	Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. <i>Lancet, The</i> , 2002, 359, 2159-2163.	6.3	235
6	Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury. <i>Pain</i> , 2000, 86, 25-32.	2.0	217
7	Histone deacetylase inhibitors: Multifunctional anticancer agents. <i>Cancer Treatment Reviews</i> , 2006, 32, 157-165.	3.4	212
8	The prenatal origins of cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 277-289.	12.8	201
9	The histone deacetylase SIRT2 stabilizes Myc oncoproteins. <i>Cell Death and Differentiation</i> , 2013, 20, 503-514.	5.0	171
10	YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of <i>FZD7</i> . <i>Cancer Research</i> , 2021, 81, 2651-2665.	0.4	150
11	SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability. <i>PLoS Genetics</i> , 2011, 7, e1002135.	1.5	136
12	The Propeptide Mediates Formation of Stromal Stores of PROMIC-1: Role in Determining Prostate Cancer Outcome. <i>Cancer Research</i> , 2005, 65, 2330-2336.	0.4	129
13	The Emerging Roles of RNA m6A Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance. <i>Cancer Research</i> , 2021, 81, 3431-3440.	0.4	129
14	Free radicals contribute to the reduction in peripheral vascular responses and the maintenance of thermal hyperalgesia in rats with chronic constriction injury. <i>Pain</i> , 1999, 79, 31-37.	2.0	122
15	Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. <i>Science Translational Medicine</i> , 2015, 7, 312ra176.	5.8	120
16	The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1. <i>Oncotarget</i> , 2014, 5, 1793-1804.	0.8	105
17	The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. <i>Clinical Cancer Research</i> , 2016, 22, 2534-2544.	3.2	100
18	Effects of a Novel Long Noncoding RNA, lncUSMycN, on N-Myc Expression and Neuroblastoma Progression. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	98

#	ARTICLE	IF	CITATIONS
19	The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression. <i>Oncotarget</i> , 2016, 7, 8663-8675.	0.8	97
20	Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18682-18687.	3.3	96
21	The regulatory role of long noncoding RNAs in cancer. <i>Cancer Letters</i> , 2017, 391, 12-19.	3.2	94
22	MYCN oncoprotein targets and their therapeutic potential. <i>Cancer Letters</i> , 2010, 293, 144-157.	3.2	92
23	A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. <i>Cancer Research</i> , 2017, 77, 971-981.	0.4	90
24	DOSim: An R package for similarity between diseases based on Disease Ontology. <i>BMC Bioinformatics</i> , 2011, 12, 266.	1.2	88
25	WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. <i>Cancer Research</i> , 2015, 75, 5143-5154.	0.4	88
26	PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 4462-4472.	3.2	85
27	Tumor Protein 53-Induced Nuclear Protein 1 Enhances p53 Function and Represses Tumorigenesis. <i>Frontiers in Genetics</i> , 2013, 4, 80.	1.1	74
28	c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis. <i>Nature Communications</i> , 2020, 11, 4980.	5.8	70
29	PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. <i>Nature Communications</i> , 2013, 4, 1508.	5.8	67
30	The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. <i>Nature Communications</i> , 2019, 10, 5026.	5.8	67
31	JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. <i>Nature Communications</i> , 2019, 10, 3319.	5.8	63
32	The Novel Long Noncoding RNA linc00467 Promotes Cell Survival but Is Down-Regulated by N-Myc. <i>PLoS ONE</i> , 2014, 9, e88112.	1.1	62
33	Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. <i>Oncogene</i> , 2013, 32, 3616-3626.	2.6	60
34	Sirtuin-1 Regulates Acinar-to-Ductal Metaplasia and Supports Cancer Cell Viability in Pancreatic Cancer. <i>Cancer Research</i> , 2013, 73, 2357-2367.	0.4	59
35	The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription. <i>Cancer Research</i> , 2017, 77, 2522-2533.	0.4	59
36	Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2020, 38, 263-278.e6.	7.7	59

#	ARTICLE	IF	CITATIONS
37	<i>IGF2BP1</i> Harbors Prognostic Significance by Gene Gain and Diverse Expression in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1285-1293.	0.8	55
38	INPP4B is an oncogenic regulator in human colon cancer. <i>Oncogene</i> , 2016, 35, 3049-3061.	2.6	52
39	Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN. <i>Cancer Research</i> , 2018, 78, 3122-3134.	0.4	48
40	Opposing Effects of Two Tissue Transglutaminase Protein Isoforms in Neuroblastoma Cell Differentiation. <i>Journal of Biological Chemistry</i> , 2010, 285, 3561-3567.	1.6	43
41	LncRNA REG1CP promotes tumorigenesis through an enhancer complex to recruit FANCI helicase for REG3A transcription. <i>Nature Communications</i> , 2019, 10, 5334.	5.8	43
42	High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients. <i>Cancer Letters</i> , 2016, 374, 315-323.	3.2	42
43	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. <i>European Journal of Cancer</i> , 2009, 45, 1846-1854.	1.3	40
44	INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. <i>Oncotarget</i> , 2015, 6, 39891-39907.	0.8	40
45	NEAT1 polyA-modulating antisense oligonucleotides reveal opposing functions for both long non-coding RNA isoforms in neuroblastoma. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 2213-2230.	2.4	39
46	FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. <i>Leukemia</i> , 2013, 27, 1053-1062.	3.3	38
47	Recognition of CRISPR/Cas9 off-target sites through ensemble learning of uneven mismatch distributions. <i>Bioinformatics</i> , 2018, 34, i757-i765.	1.8	38
48	Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. <i>Cell Death and Disease</i> , 2013, 4, e655-e655.	2.7	37
49	Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc. <i>Oncogene</i> , 2014, 33, 2987-2994.	2.6	36
50	Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. <i>Cell Death and Disease</i> , 2012, 3, e337-e337.	2.7	34
51	Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. <i>Cell Death and Disease</i> , 2016, 7, e2252-e2252.	2.7	33
52	The pan-cancer lncRNA PLANE regulates an alternative splicing program to promote cancer pathogenesis. <i>Nature Communications</i> , 2021, 12, 3734.	5.8	33
53	JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. <i>Leukemia</i> , 2019, 33, 1400-1410.	3.3	31
54	An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability. <i>Nature Communications</i> , 2021, 12, 1881.	5.8	31

#	ARTICLE	IF	CITATIONS
55	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. <i>Oncotarget</i> , 2014, 5, 10127-10139.	0.8	31
56	A p53-Responsive miRNA Network Promotes Cancer Cell Quiescence. <i>Cancer Research</i> , 2018, 78, 6666-6679.	0.4	29
57	Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against <i>MYCN</i> -amplified neuroblastoma. <i>International Journal of Cancer</i> , 2020, 147, 1928-1938.	2.3	28
58	Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2018, 138, 922-932.	0.3	26
59	Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. <i>Oncotarget</i> , 2014, 5, 4257-4268.	0.8	25
60	Enhancing the anti-angiogenic action of histone deacetylase inhibitors. <i>Molecular Cancer</i> , 2007, 6, 68.	7.9	24
61	Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface. <i>Cancer Research</i> , 2019, 79, 5652-5667.	0.4	24
62	The cyclin-dependent kinase inhibitor, p21 WAF1 , promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. <i>Carcinogenesis</i> , 2009, 30, 1865-1871.	1.3	23
63	Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A2± via AKT in prostate cancer cells. <i>Oncotarget</i> , 2014, 5, 6289-6299.	0.8	22
64	Connecting rules from paired miRNA and mRNA expression data sets of HCV patients to detect both inverse and positive regulatory relationships. <i>BMC Genomics</i> , 2015, 16, S11.	1.2	21
65	NCYM is upregulated by <i>IncUSMycN</i> and modulates N-Myc expression. <i>International Journal of Oncology</i> , 2016, 49, 2464-2470.	1.4	21
66	ACTN4 regulates the stability of RIPK1 in melanoma. <i>Oncogene</i> , 2018, 37, 4033-4045.	2.6	20
67	The histone chaperone complex FACT promotes proliferative switch of G0 cancer cells. <i>International Journal of Cancer</i> , 2019, 145, 164-178.	2.3	20
68	Targeted Therapy of <i>TERT</i> -Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1438-1451.	3.2	20
69	MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. <i>Oncotarget</i> , 2016, 7, 54937-54951.	0.8	20
70	ATP P2X receptors play little role in the maintenance of neuropathic hyperalgesia. <i>NeuroReport</i> , 2000, 11, 1669-1672.	0.6	19
71	Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach. <i>Journal of Proteomics</i> , 2014, 96, 1-12.	1.2	19
72	Zinc alleviates thermal hyperalgesia due to partial nerve injury. <i>NeuroReport</i> , 1999, 10, 1619-1623.	0.6	18

#	ARTICLE	IF	CITATIONS
73	Thymosin α 24 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. <i>Molecular Oncology</i> , 2015, 9, 1484-1500.	2.1	17
74	The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. <i>Oncotarget</i> , 2016, 7, 79217-79232.	0.8	17
75	Transcriptional regulation of G2/M regulatory proteins and perturbation of G2/M Cell cycle transition by a traditional Chinese medicine recipe. <i>Journal of Ethnopharmacology</i> , 2020, 251, 112526.	2.0	16
76	Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5098.	1.8	16
77	Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design. <i>Briefings in Functional Genomics</i> , 2021, 20, 289-303.	1.3	16
78	The Relationship of Serum Macrophage Inhibitory Cytokine α 1 Levels with Gray Matter Volumes in Community-Dwelling Older Individuals. <i>PLoS ONE</i> , 2015, 10, e0123399.	1.1	16
79	Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase. <i>European Journal of Cancer</i> , 2012, 48, 3278-3287.	1.3	15
80	Upregulation of LYAR induces neuroblastoma cell proliferation and survival. <i>Cell Death and Differentiation</i> , 2017, 24, 1645-1654.	5.0	15
81	Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells. <i>Theranostics</i> , 2021, 11, 9605-9622.	4.6	14
82	An inverse relationship between serum macrophage inhibitory cytokine-1 levels and brain white matter integrity in community-dwelling older individuals. <i>Psychoneuroendocrinology</i> , 2015, 62, 80-88.	1.3	13
83	Delineation of the frequency and boundary of chromosomal copy number variations in paediatric neuroblastoma. <i>Cell Cycle</i> , 2018, 17, 749-758.	1.3	13
84	A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma. <i>Oncogene</i> , 2021, 40, 2367-2381.	2.6	13
85	The RNA α helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma. <i>Molecular Oncology</i> , 2021, 15, 1162-1179.	2.1	12
86	CPF impedes cell cycle re α entry of quiescent lung cancer cells through transcriptional suppression of FACT and c α MYC. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2229-2239.	1.6	11
87	Gaq signaling is required for the maintenance of MLL-AF9-induced acute myeloid leukemia. <i>Leukemia</i> , 2016, 30, 1745-1748.	3.3	9
88	Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein. <i>Oncology Reports</i> , 2014, 31, 1935-1939.	1.2	8
89	Amide-based derivatives of β -alanine hydroxamic acid as histone deacetylase inhibitors: Attenuation of potency through resonance effects. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6200-6204.	1.0	7
90	Up-regulation of Survivin during Immortalization of Human Myofibroblasts Is Linked to Repression of Tumor Suppressor p16INK4a Protein and Confers Resistance to Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2013, 288, 12032-12041.	1.6	7

#	ARTICLE	IF	CITATIONS
91	LVA influenced the SIRT1-miR-27a-p53-SMAD2-MMP1/COL1/BCL2 axis in human skin primary fibroblasts. Journal of Cellular and Molecular Medicine, 2020, 24, 10027-10041.	1.6	7
92	Advances in therapeutic agents targeting quiescent cancer cells. , 2022, 1, .		6
93	Apigenin impedes cell cycle progression at G2 phase in prostate cancer cells. Discover Oncology, 2022, 13, .	0.8	6
94	The Histone Demethylase NO66 Induces Glioma Cell Proliferation. Anticancer Research, 2019, 39, 6007-6014.	0.5	5
95	Association of GDF-15 and Syntax Score in Patient with Acute Myocardial Infarction. Cardiovascular Therapeutics, 2019, 2019, 1-6.	1.1	4
96	Sequencing dropout-and-batch effect normalization for single-cell mRNA profiles: a survey and comparative analysis. Briefings in Bioinformatics, 2020, 22, .	3.2	4
97	Neuroblastoma: A Malignancy Due to Cell Differentiation Block. , 0, , .		3
98	Up-regulation of LYAR blocks Myc-induced cell death. Cell Cycle, 2017, 16, 1857-1858.	1.3	2
99	Abstract 146: The long noncoding RNA MALAT1 promotes hypoxia-driven angiogenesis by upregulating pro-angiogenic gene expression in neuroblastoma cells. Cancer Research, 2015, 75, 146-146.	0.4	2
100	Abstract 2450: MYCN and TFAP4 promote neuroblastoma malignancy by cooperating in the regulation a subset of target genes involved in cancer cell growth and metastasis. , 2016, , .		2
101	Chromosome preference of disease genes and vectorization for the prediction of non-coding disease genes. Oncotarget, 2017, 8, 78901-78916.	0.8	2
102	Abstract 3876: TRIM16 is a prognostic marker for patients with lymph node metastatic melanoma.. , 2013, , .		1
103	Abstract 2664: Eradication of neuroblastoma by suppressing the expression of a single long noncoding RNA. Cancer Research, 2016, 76, 2664-2664.	0.4	1
104	Abstract LB-080: The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription. , 2017, , .		1
105	Abstract 2523: Cooperativity of HOXA5 and STAT3 is critical for HDAC8 inhibition-mediated transcriptional activation of PD-L1 in human melanoma cells. Cancer Research, 2018, 78, 2523-2523.	0.4	1
106	Abstract 2196: Upregulation of survivin during immortalization is linked to repression of p16INK4a and confers resistance to oxidative stress. , 2012, , .		0
107	Abstract 5043: The facilitates chromatin transcription (FACT) protein complex promotes neuroblastoma tumor initiation.. , 2013, , .		0
108	Abstract 2985: The histone demethylase JMJD1A induces neuroblastoma cell migration and invasion.. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
109	Abstract 5005: The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1. , 2014, , .		0
110	Abstract 1378: The histone methyltransferase adaptor WDR5 is a novel cofactor in neuroblastoma. , 2014, , .		0
111	Abstract 5138: Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. , 2014, , .		0
112	Abstract 3103: IGF2BP1 and MYCN cooperate in an oncogenic feedback loop, in high-risk neuroblastoma. , 2014, , .		0
113	Abstract 1403: TRIM16 inhibits cell growth through direct interaction and modulation of TDP43 protein stability in cancer cells. , 2014, , .		0
114	Abstract 4718: Inositol polyphosphate 4-phosphatase II activates PI3K/SGK3 signaling to promote proliferation of human melanoma cells. , 2015, , .		0
115	Abstract 962: PA2G4 predicts poor prognosis in neuroblastoma patients and promotes neuroblastoma progression by enhancing MYCN protein stability. , 2015, , .		0
116	Abstract PR09: MYCN and is a therapeutic target in neuroblastoma. , 2015, , .		0
117	Abstract B13: Eradication of neuroblastoma by suppressing the expression of a single long noncoding RNA. , 2016, , .		0
118	Abstract LB-149: LYAR promotes cell proliferation by repressing CHAC1 expression in neuroblastoma. , 2016, , .		0
119	Abstract 52: A genomic editing approach for purification of viable quiescent cancer cells. , 2018, , .		0
120	Abstract 3659: Alyref is a novel binding partner and co-factor for MYCN-driven oncogenesis in neuroblastoma. , 2019, , .		0
121	Abstract 5209: Efficacious targeting of TERT oncogene rearrangement with BET bromodomain inhibitor and proteasome inhibitor combination therapy. , 2019, , .		0
122	Abstract 5721: The super-enhancer driven long noncoding RNA lncNB promotes neuroblastoma tumorigenesis. , 2020, , .		0
123	Abstract 4504: MILIP is a pan cancer-associated long noncoding RNA that links MYC to inactivation of p53. , 2019, , .		0